Conceivably, ARF null tumors may present a different secretome profile, which may abrogate SASP-dependent autocrine and paracrine positive feedback loops and elicit incomplete targeting and clearance of tumor cells by immune effectors. Here, CDKN2A is linked to neoplasm.